Stuart A Forman1. 1. Department of Anesthesia Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. saforman@partners.org
Abstract
PURPOSE OF REVIEW: Formal Monod-Wyman-Changeux allosteric mechanisms have proven valuable in framing research on the mechanism of etomidate action on its major molecular targets, γ-aminobutyric acid type A (GABAA) receptors. However, the mathematical formalism of these mechanisms makes them difficult to comprehend. RECENT FINDINGS: We illustrate how allosteric models represent shifting equilibria between various functional receptor states (closed versus open) and how co-agonism can be readily understood as simply addition of gating energy associated with occupation of distinct agonist sites. We use these models to illustrate how the functional effects of a point mutation, α1M236W, in GABAA receptors can be translated into an allosteric model phenotype. SUMMARY: Allosteric co-agonism provides a robust framework for design and interpretation of structure-function experiments aimed at understanding where and how etomidate affects its GABAA receptor target molecules.
PURPOSE OF REVIEW: Formal Monod-Wyman-Changeux allosteric mechanisms have proven valuable in framing research on the mechanism of etomidate action on its major molecular targets, γ-aminobutyric acid type A (GABAA) receptors. However, the mathematical formalism of these mechanisms makes them difficult to comprehend. RECENT FINDINGS: We illustrate how allosteric models represent shifting equilibria between various functional receptor states (closed versus open) and how co-agonism can be readily understood as simply addition of gating energy associated with occupation of distinct agonist sites. We use these models to illustrate how the functional effects of a point mutation, α1M236W, in GABAA receptors can be translated into an allosteric model phenotype. SUMMARY: Allosteric co-agonism provides a robust framework for design and interpretation of structure-function experiments aimed at understanding where and how etomidate affects its GABAA receptor target molecules.
Authors: S Shaukat Husain; Michael R Ziebell; Dirk Ruesch; Filbert Hong; Enrique Arevalo; Jonathan A Kosterlitz; Richard W Olsen; Stuart A Forman; Jonathan B Cohen; Keith W Miller Journal: J Med Chem Date: 2003-03-27 Impact factor: 7.446
Authors: Delia Belelli; Anna-Lisa Muntoni; Simon D Merrywest; Luc J Gentet; Anna Casula; Helen Callachan; Paola Madau; David K Gemmell; Niall M Hamilton; Jeremy J Lambert; Keith T Sillar; John A Peters Journal: Neuropharmacology Date: 2003-07 Impact factor: 5.250
Authors: Ervin Pejo; Peter Santer; Lei Wang; Philip Dershwitz; S Shaukat Husain; Douglas E Raines Journal: Anesthesiology Date: 2016-03 Impact factor: 7.892
Authors: Daniel J Shin; Allison L Germann; Douglas F Covey; Joe Henry Steinbach; Gustav Akk Journal: Mol Pharmacol Date: 2018-10-18 Impact factor: 4.436
Authors: Suzzane Horani; Evan P Stater; Pierre-Jean Corringer; James R Trudell; R Adron Harris; Rebecca J Howard Journal: Alcohol Clin Exp Res Date: 2015-05-14 Impact factor: 3.455
Authors: Celena Ma; Ervin Pejo; Megan McGrath; Selwyn S Jayakar; Xiaojuan Zhou; Keith W Miller; Jonathan B Cohen; Douglas E Raines Journal: Anesthesiology Date: 2017-11 Impact factor: 7.892
Authors: David C Chiara; Selwyn S Jayakar; Xiaojuan Zhou; Xi Zhang; Pavel Y Savechenkov; Karol S Bruzik; Keith W Miller; Jonathan B Cohen Journal: J Biol Chem Date: 2013-05-15 Impact factor: 5.157